Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hypersensitivity Reaction

  Free Subscription


Articles published in Eur J Dermatol

Retrieve available abstracts of 31 articles:
HTML format



Single Articles


    August 2021
  1. ASANO A, Nakai K, Hayashi D, Hashimoto T, et al
    A case of delgocitinib-indued anti-LAD-1 IgG-positive, anti-BP180 NC16A IgG-negative bullous pemphigoid in a patient with atopic dermatitis.
    Eur J Dermatol. 2021 Aug 17. pii: ejd.2021.4105. doi: 10.1684/ejd.2021.4105.
    PubMed    


    June 2021
  2. ZHANG Z, Li H, Zhang H, Cheng R, et al
    Factors associated with persistence of early-onset atopic dermatitis up to the age of 12 years: a prospective cohort study in China.
    Eur J Dermatol. 2021;31:403-408.
    PubMed     Abstract available


    April 2021
  3. SUN J, Gu Y, Li K, Zhang JZ, et al
    Co-existence of specific IgE antibodies and T cells reactive to house dust mites and human transglutaminase3/tropomysin in patients with atopic dermatitis.
    Eur J Dermatol. 2021 Apr 16. pii: ejd.2021.4018. doi: 10.1684/ejd.2021.4018.
    PubMed     Abstract available


  4. MICHELOTTI A, Cestone E, De Ponti I, Giardina S, et al
    Efficacy of a probiotic supplement in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled clinical trial.
    Eur J Dermatol. 2021 Apr 16. pii: ejd.2021.4019. doi: 10.1684/ejd.2021.4019.
    PubMed     Abstract available


  5. PINO LOPEZ J, Kromer C, Herr R, Schmieder A, et al
    Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients.
    Eur J Dermatol. 2021 Apr 16. pii: ejd.2021.4020. doi: 10.1684/ejd.2021.4020.
    PubMed     Abstract available


  6. PAN C, Cheng R, Li Y, Zhao M, et al
    Deep-intronic and frameshift DSG1 variants associated with atypical severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome in a Chinese family.
    Eur J Dermatol. 2021 Apr 5. pii: ejd.2021.4012. doi: 10.1684/ejd.2021.4012.
    PubMed     Abstract available


  7. GIORDANO-LABADIE F, Becherel PA, Pralong P, Outtas O, et al
    Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Eur J Dermatol. 2021;31:217-224.
    PubMed     Abstract available


    March 2021
  8. KIRSTEN N, Mohr N, Maul JT, Augustin M, et al
    Incidence of atopic conditions in people with psoriasis: a population-based analysis.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3963. doi: 10.1684/ejd.2021.3963.
    PubMed     Abstract available


    February 2021
  9. BELBEZIER A, Boccon-Gibod I, Bouillet L
    Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Eur J Dermatol. 2021;31:86-87.
    PubMed    


  10. KOMATSU-FUJII T, Ogawa M, Nonoyama S, Fukumoto T, et al
    Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1(R)) after nivolumab discontinuation.
    Eur J Dermatol. 2021;31:98-99.
    PubMed    


  11. KUMANO Y, Nagai A, Sugiura K
    Erythro-papular type drug eruption caused by fosravuconazole L-lysine ethanolate.
    Eur J Dermatol. 2021;31:90-91.
    PubMed    


  12. UGAJIN T, Namiki T, Yokozeki H
    A case of prurigo caused by hair dye containing p-phenylenediamine: histopathological findings.
    Eur J Dermatol. 2021;31:103-104.
    PubMed    


  13. MAKIHARA-INUKAI M, Takeichi T, Ogawa-Momohara M, Muro Y, et al
    Morphea in a Crohn's disease patient undergoing ustekinumab treatment.
    Eur J Dermatol. 2021;31:96-97.
    PubMed    


  14. FAUCON C, Bernigaud C, Sbidian E, Hue S, et al
    Essential oils as potential triggers for bullous pemphigoid? A report of two patients.
    Eur J Dermatol. 2021;31:92-93.
    PubMed    


  15. HAYAMA K, Fujita H, Asai-Sato M, Kawana K, et al
    Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Eur J Dermatol. 2021;31:100-101.
    PubMed    


    January 2021
  16. NAKAGAWA M, Hanada M, Inomata N, Amano H, et al
    A case of a gibberellin-regulated protein-positive patient allergic to various fruits.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3949. doi: 10.1684/ejd.2020.3949.
    PubMed    


  17. NAGASAWA Y, Iinuma S, Fujii M, Kanno K, et al
    Dasatinib-induced panniculitis in a patient with chronic myeloid leukaemia.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3946. doi: 10.1684/ejd.2020.3946.
    PubMed    


  18. COSTEDOAT I, Vergara R, Dousset L, Gerard E, et al
    Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod.
    Eur J Dermatol. 2021 Jan 15. pii: ejd.2020.3951. doi: 10.1684/ejd.2020.3951.
    PubMed    


    December 2020
  19. DANSET M, Hacard F, Jaulent C, Nosbaum A, et al
    Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Eur J Dermatol. 2020 Dec 18. pii: ejd.2020.3910. doi: 10.1684/ejd.2020.3910.
    PubMed    


  20. VERALDI S, Romagnuolo M, Benzecry V
    Urticaria as a first clinical manifestation of COVID-19.
    Eur J Dermatol. 2020;30:737-738.
    PubMed    


  21. APALLA Z, Sidiropoulos T, Kampouropoulou E, Papageorgiou M, et al
    Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
    Eur J Dermatol. 2020;30:716-722.
    PubMed     Abstract available


    November 2020
  22. KIMURA R, Sugita K, Yamamoto O
    Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Eur J Dermatol. 2020 Nov 24. pii: ejd.2020.3904. doi: 10.1684/ejd.2020.3904.
    PubMed    


    October 2020
  23. PARADISI A, Abeni D, Didona D, Ricci F, et al
    A new case series on etanercept treatment for toxic epidermal necrolysis.
    Eur J Dermatol. 2020 Oct 6. pii: ejd.2020.3883. doi: 10.1684/ejd.2020.3883.
    PubMed     Abstract available


  24. XIONG H, Liu G, Xiao J, Han Y, et al
    Recurrence of Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol and piroxicam.
    Eur J Dermatol. 2020;30:620-621.
    PubMed    


  25. KROMER C, Schon MP, Mossner R
    Eczematous eruption in patients with psoriasis during risankizumab treatment.
    Eur J Dermatol. 2020;30:599-601.
    PubMed    


    August 2020
  26. KRASTEVA M, Caratas-Perifan M, Kock M, Koch T, et al
    Contact allergy to hair-colouring products: a cosmetovigilance follow-up study by four companies in Europe from 2014 to 2017.
    Eur J Dermatol. 2020;30:377-388.
    PubMed     Abstract available


    June 2020
  27. NAM KH, Park SW, Jung ES, Lee SK, et al
    A case of pityriasis lichenoides et varioliformis acuta after topical application of diphenylcyclopropenone.
    Eur J Dermatol. 2020 Jun 14. pii: ejd.2020.3790. doi: 10.1684/ejd.2020.3790.
    PubMed    


  28. SHIBATA A, Ishiguro Y, Makita S, Yamaga Y, et al
    A systemic form chronic active Epstein-Barr virus infection diagnosed from erythema nodosum-like skin lesions.
    Eur J Dermatol. 2020;30:314-316.
    PubMed    


    April 2020
  29. LIU S, Xu Q, Xu Y, Wang X, et al
    Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional survey.
    Eur J Dermatol. 2020;30:169-176.
    PubMed     Abstract available


  30. SAKAI T, Matsuda-Hirose H, Shimada H, Sugiura K, et al
    Generalized pustular psoriasis-like drug eruption manifested by systemic glucocorticosteroid in a patient without IL36RN mutation or an immunological disorder.
    Eur J Dermatol. 2020;30:183-184.
    PubMed    


    February 2020
  31. YANG F, Chen Z, Chen SA, Zhu Q, et al
    Clinical profile of cutaneous adverse drug reactions: a retrospective study of 1883 hospitalized patients from 2007 to 2016 in Shanghai, China.
    Eur J Dermatol. 2020 Feb 6. pii: ejd.2020.3713. doi: 10.1684/ejd.2020.3713.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: